Understand the source comparison
Best Peptides for Fibromyalgia: Treatment Comparison
Thymosin Alpha-1 Immune modulation (Treg upregulation, cytokine normalization) 1.6mg subcutaneous, twice weekly for 12+ weeks 18-point FIQ reduction vs 4-point placebo in pilot trial; reduced IL-6 and TNF-alpha Subcutaneous injection Strongest evidence for imm
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- Immune modulation (Treg upregulation, cytokine normalization)
- 1.6mg subcutaneous, twice weekly for 12+ weeks
- 18-point FIQ reduction vs 4-point placebo in pilot trial; reduced IL-6 and TNF-alpha
- Subcutaneous injection
- Strongest evidence for immune-mediated fibromyalgia subtypes with documented cytokine elevation
- BPC-157
- Tissue repair, neuroinflammation reduction, mitochondrial support
- 250–500mcg subcutaneous daily for 4–8 weeks
- Preclinical: 35–50% reduction in oxidative stress markers; anecdotal pain reduction in soft-tissue injury
- Subcutaneous or oral (gastric-stable)
- Mechanistically sound but lacking fibromyalgia-specific human trials. Best for patients with documented tissue injury or mitochondrial dysfunction
- Cerebrolysin
- Neurotrophic support, NMDA modulation, neuroplasticity
- 30ml IV daily × 10 days, then twice weekly × 8 weeks
- RCT: 4.2-point VAS reduction vs 1.8 placebo; 3.1-point MoCA cognitive improvement
- Intravenous (clinic-administered)
- Backed by controlled trial data but requires clinical administration. Strongest evidence for cognitive fog and central sensitization
- MK 677
- GH secretagogue (ghrelin mimetic), sleep architecture improvement
- 25mg oral nightly
- 60–90% IGF-1 increase; 4.8-point PSQI sleep improvement; 45-minute reduction in morning stiffness
- Oral (once daily)
- Best option for patients with documented GH deficiency or poor sleep quality. Oral convenience is a major practical advantage
- CJC1295/Ipamorelin
- Pulsatile GH release (GHRH + ghrelin analog)
- 100–200mcg each, subcutaneous before bed
- Anecdotal: improved recovery, reduced flare severity
- Mimics natural GH secretion better than continuous dosing but lacks fibromyalgia-specific trial data
- KPV
- NF-kB inhibition (anti-inflammatory transcription factor blockade)
- 500mcg–2mg oral or subcutaneous daily
- Preclinical: 40–60% TNF-alpha/IL-1beta reduction in colitis models
- Oral or subcutaneous
- Mechanistically promising for cytokine-driven pain but human fibromyalgia data absent. Experimental stage